263 related articles for article (PubMed ID: 18354252)
1. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.
Costa E; Pereira BJ; Rocha-Pereira P; Rocha S; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252
[TBL] [Abstract][Full Text] [Related]
2. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
3. Does hepcidin affect erythropoiesis in hemodialysis patients?
Eleftheriadis T; Kartsios C; Liakopoulos V; Antoniadi G; Ditsa M; Papadopoulos C; Anifandis G; Skirta A; Markala D; Stefanidis I
Acta Haematol; 2006; 116(4):238-44. PubMed ID: 17119323
[TBL] [Abstract][Full Text] [Related]
4. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
5. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients.
Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A
J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926
[TBL] [Abstract][Full Text] [Related]
6. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
[TBL] [Abstract][Full Text] [Related]
7. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
8. The relationship between reticulocyte hemoglobin content with C-reactive protein and conventional iron parameters in dialysis patients.
Hackeng CM; Beerenhout CM; Hermans M; Van der Kuy PH; Van der Dussen H; Van Dieijen-Visser MP; Hamulyák K; Van der Sande FM; Leunissen KM; Kooman JP
J Nephrol; 2004; 17(1):107-11. PubMed ID: 15151266
[TBL] [Abstract][Full Text] [Related]
9. [Pro-hepcidin, its relation with indicators of iron metabolism and of inflammation in patients hemodialyzed treated or not with recombinant erythropoietin].
Barrios Y; Espinoza M; Barón MA
Nutr Hosp; 2010; 25(4):555-60. PubMed ID: 20694291
[TBL] [Abstract][Full Text] [Related]
10. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
Malyszko J; Malyszko JS; Mysliwiec M
Kidney Blood Press Res; 2009; 32(4):235-8. PubMed ID: 19713706
[TBL] [Abstract][Full Text] [Related]
11. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
[TBL] [Abstract][Full Text] [Related]
12. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis.
Rosenlöf K; Kivivuori SM; Grönhagen-Riska C; Teppo AM; Slimes MA
Clin Nephrol; 1995 Apr; 43(4):249-55. PubMed ID: 7606879
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
Costa E; Rocha S; Rocha-Pereira P; Nascimento H; Castro E; Miranda V; Faria Mdo S; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Am J Nephrol; 2008; 28(6):935-40. PubMed ID: 18587235
[TBL] [Abstract][Full Text] [Related]
14. Influence of inflammation on the relation between markers of iron deficiency in renal replacement therapy.
Yavuz A; Akbaş SH; Tuncer M; Kolağasi O; Cetinkaya R; Gürkan A; Demirbaş A; Gultekin M; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):41-3. PubMed ID: 15013295
[TBL] [Abstract][Full Text] [Related]
15. Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients.
do Sameiro-Faria M; Ribeiro S; Rocha-Pereira P; Fernandes J; Reis F; Bronze-da-Rocha E; Miranda V; Quintanilha A; Costa E; Belo L; Santos-Silva A
Ren Fail; 2013; 35(10):1392-8. PubMed ID: 23991655
[TBL] [Abstract][Full Text] [Related]
16. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.
Malyszko J; Malyszko JS; Kozminski P; Mysliwiec M
Ren Fail; 2009; 31(10):876-83. PubMed ID: 20030521
[TBL] [Abstract][Full Text] [Related]
17. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients.
Arabul M; Gullulu M; Yilmaz Y; Eren MA; Baran B; Gul CB; Kocamaz G; Dilek K
Med Sci Monit; 2009 Nov; 15(11):CR583-7. PubMed ID: 19865058
[TBL] [Abstract][Full Text] [Related]
18. Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M.
Beirão I; Almeida S; Swinkels D; Costa PM; Moreira L; Fonseca I; Freitas C; Cabrita A; Porto G
Blood Cells Mol Dis; 2008; 41(2):175-8. PubMed ID: 18544472
[TBL] [Abstract][Full Text] [Related]
19. Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients.
Lin TJ; Liao LY; Chou JM; Liu SO; Wang CK
Hepatogastroenterology; 2009; 56(93):1146-51. PubMed ID: 19760959
[TBL] [Abstract][Full Text] [Related]
20. Regulation of hepcidin: insights from biochemical analyses on human serum samples.
Kemna EH; Kartikasari AE; van Tits LJ; Pickkers P; Tjalsma H; Swinkels DW
Blood Cells Mol Dis; 2008; 40(3):339-46. PubMed ID: 18023212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
